| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 84 | 2025 | 620 | 10.350 |
Why?
|
| Melanoma | 42 | 2025 | 495 | 4.870 |
Why?
|
| Nevus, Pigmented | 15 | 2025 | 58 | 3.510 |
Why?
|
| Melanocytes | 21 | 2025 | 60 | 3.260 |
Why?
|
| Skin | 29 | 2020 | 578 | 2.110 |
Why?
|
| Skin Diseases | 10 | 2023 | 174 | 1.780 |
Why?
|
| Organizational Innovation | 4 | 2018 | 40 | 1.630 |
Why?
|
| Dysplastic Nevus Syndrome | 5 | 2024 | 10 | 1.560 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 108 | 1.390 |
Why?
|
| Primary Health Care | 6 | 2024 | 378 | 1.390 |
Why?
|
| Telemedicine | 4 | 2022 | 225 | 1.380 |
Why?
|
| Immunohistochemistry | 32 | 2021 | 1799 | 1.260 |
Why?
|
| Electronic Health Records | 5 | 2021 | 372 | 1.260 |
Why?
|
| Humans | 200 | 2025 | 93511 | 1.240 |
Why?
|
| Dermatitis | 3 | 2024 | 34 | 1.170 |
Why?
|
| Drug Eruptions | 5 | 2025 | 34 | 1.170 |
Why?
|
| Quality Improvement | 5 | 2024 | 485 | 1.080 |
Why?
|
| Mycosis Fungoides | 6 | 2023 | 30 | 1.040 |
Why?
|
| Diagnosis, Differential | 31 | 2025 | 1546 | 0.970 |
Why?
|
| Meaningful Use | 2 | 2016 | 4 | 0.930 |
Why?
|
| Health Plan Implementation | 5 | 2017 | 63 | 0.830 |
Why?
|
| Stroke | 2 | 2022 | 1079 | 0.740 |
Why?
|
| Academic Medical Centers | 2 | 2024 | 394 | 0.720 |
Why?
|
| Organophosphonates | 1 | 2021 | 46 | 0.700 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.690 |
Why?
|
| Papilloma | 3 | 2021 | 23 | 0.660 |
Why?
|
| Female | 94 | 2025 | 48698 | 0.660 |
Why?
|
| Male | 79 | 2025 | 44553 | 0.650 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 110 | 0.650 |
Why?
|
| Community Health Services | 1 | 2021 | 81 | 0.640 |
Why?
|
| Patient Portals | 1 | 2020 | 21 | 0.640 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 481 | 0.630 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 122 | 0.630 |
Why?
|
| Nevus | 4 | 2024 | 18 | 0.630 |
Why?
|
| Needs Assessment | 1 | 2021 | 168 | 0.630 |
Why?
|
| Dermatology | 2 | 2012 | 46 | 0.610 |
Why?
|
| Information Dissemination | 2 | 2017 | 124 | 0.610 |
Why?
|
| Skin Ulcer | 3 | 2015 | 27 | 0.610 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2019 | 7 | 0.600 |
Why?
|
| Health Equity | 1 | 2021 | 101 | 0.590 |
Why?
|
| Middle Aged | 59 | 2025 | 27569 | 0.570 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 6 | 0.570 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 18 | 0.560 |
Why?
|
| Pharmacists | 1 | 2018 | 36 | 0.560 |
Why?
|
| Epidermis | 12 | 2021 | 103 | 0.560 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 300 | 0.550 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2024 | 1077 | 0.550 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 383 | 0.540 |
Why?
|
| Aged | 48 | 2025 | 20430 | 0.540 |
Why?
|
| Keratosis | 3 | 2011 | 21 | 0.530 |
Why?
|
| Adult | 57 | 2025 | 27918 | 0.520 |
Why?
|
| Interviews as Topic | 6 | 2024 | 364 | 0.520 |
Why?
|
| Terminology as Topic | 3 | 2025 | 218 | 0.520 |
Why?
|
| Community Participation | 1 | 2017 | 38 | 0.520 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2014 | 64 | 0.510 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 3 | 2024 | 7 | 0.500 |
Why?
|
| Pemphigus | 3 | 2012 | 14 | 0.500 |
Why?
|
| Research Personnel | 1 | 2017 | 82 | 0.500 |
Why?
|
| Antineoplastic Agents | 6 | 2016 | 2303 | 0.500 |
Why?
|
| Biopsy | 13 | 2023 | 1175 | 0.500 |
Why?
|
| Histiocytoma, Benign Fibrous | 4 | 2020 | 23 | 0.480 |
Why?
|
| Dermatofibrosarcoma | 4 | 2001 | 13 | 0.480 |
Why?
|
| Skin Diseases, Papulosquamous | 3 | 2011 | 5 | 0.470 |
Why?
|
| Qualitative Research | 3 | 2024 | 347 | 0.460 |
Why?
|
| Herpesvirus 4, Human | 2 | 2015 | 122 | 0.460 |
Why?
|
| North Carolina | 5 | 2024 | 56 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2017 | 80 | 0.450 |
Why?
|
| Skin Aging | 3 | 2024 | 31 | 0.440 |
Why?
|
| Reimbursement, Incentive | 1 | 2014 | 36 | 0.430 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 751 | 0.430 |
Why?
|
| Biomarkers, Tumor | 13 | 2024 | 1660 | 0.430 |
Why?
|
| Cicatrix | 2 | 2011 | 74 | 0.420 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2005 | 7 | 0.420 |
Why?
|
| Stem Cells | 2 | 2013 | 387 | 0.420 |
Why?
|
| Leadership | 1 | 2016 | 148 | 0.420 |
Why?
|
| Antigens, CD34 | 6 | 2001 | 161 | 0.420 |
Why?
|
| Ultraviolet Rays | 8 | 2017 | 192 | 0.420 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 452 | 0.410 |
Why?
|
| Membrane Glycoproteins | 7 | 2006 | 444 | 0.410 |
Why?
|
| Arsenic Poisoning | 2 | 2013 | 104 | 0.400 |
Why?
|
| Ambulatory Care | 1 | 2014 | 193 | 0.390 |
Why?
|
| Muir-Torre Syndrome | 1 | 2012 | 5 | 0.380 |
Why?
|
| Keratinocytes | 10 | 2021 | 146 | 0.380 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2012 | 8 | 0.380 |
Why?
|
| Health Services Research | 3 | 2018 | 142 | 0.380 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 26 | 0.380 |
Why?
|
| Face | 2 | 2024 | 109 | 0.380 |
Why?
|
| Child | 16 | 2024 | 7355 | 0.360 |
Why?
|
| Psoriasis | 3 | 2014 | 254 | 0.360 |
Why?
|
| Transcriptome | 5 | 2025 | 762 | 0.360 |
Why?
|
| Pruritus | 2 | 2016 | 30 | 0.360 |
Why?
|
| Arsenic | 3 | 2025 | 272 | 0.350 |
Why?
|
| Pityriasis Rubra Pilaris | 1 | 2011 | 3 | 0.350 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2011 | 4 | 0.350 |
Why?
|
| Noninvasive Ventilation | 2 | 2022 | 41 | 0.350 |
Why?
|
| Dapsone | 1 | 2011 | 11 | 0.350 |
Why?
|
| Adolescent | 20 | 2025 | 9606 | 0.350 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 464 | 0.350 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2011 | 9 | 0.350 |
Why?
|
| Carcinoma, Basal Cell | 7 | 2024 | 63 | 0.350 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 49 | 0.340 |
Why?
|
| Carcinogenesis | 3 | 2021 | 235 | 0.340 |
Why?
|
| Bridged-Ring Compounds | 1 | 2011 | 16 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1448 | 0.330 |
Why?
|
| Taxoids | 1 | 2011 | 126 | 0.330 |
Why?
|
| Adenoma | 1 | 2012 | 258 | 0.320 |
Why?
|
| Parakeratosis | 1 | 2010 | 1 | 0.320 |
Why?
|
| Cell Nucleus Shape | 1 | 2010 | 2 | 0.320 |
Why?
|
| Cell Nucleus Size | 1 | 2010 | 2 | 0.320 |
Why?
|
| World Health Organization | 3 | 2025 | 121 | 0.320 |
Why?
|
| Warts | 1 | 2010 | 12 | 0.320 |
Why?
|
| Benzimidazoles | 1 | 2011 | 112 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 1338 | 0.320 |
Why?
|
| Sarcoidosis | 1 | 2011 | 92 | 0.310 |
Why?
|
| Phototherapy | 4 | 2005 | 34 | 0.310 |
Why?
|
| United States | 8 | 2024 | 7619 | 0.310 |
Why?
|
| Health Personnel | 2 | 2024 | 234 | 0.300 |
Why?
|
| Hospice Care | 2 | 2019 | 40 | 0.300 |
Why?
|
| Pyridines | 1 | 2011 | 303 | 0.300 |
Why?
|
| Neoplasm Proteins | 8 | 2020 | 537 | 0.300 |
Why?
|
| Water Pollutants, Chemical | 1 | 2011 | 140 | 0.300 |
Why?
|
| Neoplasm Grading | 3 | 2024 | 402 | 0.300 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 1847 | 0.300 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2005 | 124 | 0.300 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 537 | 0.300 |
Why?
|
| Sirtuin 1 | 3 | 2014 | 36 | 0.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 306 | 0.280 |
Why?
|
| Pathology, Clinical | 1 | 2008 | 38 | 0.280 |
Why?
|
| Keratosis, Actinic | 2 | 2023 | 13 | 0.280 |
Why?
|
| BCG Vaccine | 2 | 2023 | 37 | 0.280 |
Why?
|
| Oxidoreductases | 2 | 1998 | 111 | 0.280 |
Why?
|
| Vulvar Neoplasms | 2 | 2018 | 19 | 0.270 |
Why?
|
| Terminal Care | 2 | 2019 | 146 | 0.270 |
Why?
|
| Dermatitis, Atopic | 3 | 2025 | 65 | 0.270 |
Why?
|
| Mutation | 8 | 2024 | 4272 | 0.270 |
Why?
|
| Photochemotherapy | 5 | 2009 | 100 | 0.270 |
Why?
|
| Herpes Simplex | 3 | 2001 | 79 | 0.270 |
Why?
|
| Observer Variation | 5 | 2024 | 570 | 0.270 |
Why?
|
| Health Care Surveys | 3 | 2019 | 285 | 0.260 |
Why?
|
| Sunlight | 3 | 2011 | 27 | 0.260 |
Why?
|
| Rejuvenation | 2 | 2024 | 20 | 0.260 |
Why?
|
| Autophagy | 2 | 2021 | 172 | 0.260 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 255 | 0.260 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 145 | 0.250 |
Why?
|
| Apoptosis | 6 | 2014 | 1721 | 0.250 |
Why?
|
| Radiation-Sensitizing Agents | 6 | 2000 | 97 | 0.250 |
Why?
|
| Rhodamines | 4 | 1990 | 20 | 0.250 |
Why?
|
| Hamartoma | 2 | 2024 | 33 | 0.250 |
Why?
|
| Herpesvirus 8, Human | 1 | 2006 | 10 | 0.250 |
Why?
|
| Sarcoma, Kaposi | 1 | 2006 | 17 | 0.250 |
Why?
|
| Plasmacytoma | 1 | 2006 | 26 | 0.250 |
Why?
|
| Castleman Disease | 1 | 2006 | 12 | 0.250 |
Why?
|
| Decision Making | 1 | 2012 | 674 | 0.240 |
Why?
|
| Retrospective Studies | 11 | 2021 | 10164 | 0.240 |
Why?
|
| Mucins | 3 | 2005 | 40 | 0.240 |
Why?
|
| Alopecia | 3 | 2002 | 35 | 0.240 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 870 | 0.240 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 7061 | 0.230 |
Why?
|
| Palliative Care | 4 | 2022 | 269 | 0.230 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2011 | 147 | 0.230 |
Why?
|
| Xanthenes | 3 | 1990 | 22 | 0.230 |
Why?
|
| Nevus, Blue | 3 | 2016 | 5 | 0.230 |
Why?
|
| Ossification, Heterotopic | 1 | 2005 | 32 | 0.230 |
Why?
|
| Eczema | 1 | 2025 | 10 | 0.230 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2025 | 21 | 0.230 |
Why?
|
| Hidrocystoma | 1 | 2005 | 1 | 0.230 |
Why?
|
| Apocrine Glands | 1 | 2005 | 3 | 0.230 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2025 | 29 | 0.220 |
Why?
|
| Diagnostic Errors | 3 | 2015 | 157 | 0.220 |
Why?
|
| Dermal Fillers | 1 | 2024 | 3 | 0.220 |
Why?
|
| Prenatal Care | 1 | 2025 | 80 | 0.220 |
Why?
|
| Carcinoid Tumor | 1 | 2005 | 45 | 0.220 |
Why?
|
| Polyesters | 1 | 2024 | 44 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 292 | 0.210 |
Why?
|
| Chondrosarcoma | 2 | 2001 | 54 | 0.210 |
Why?
|
| Cosmetic Techniques | 1 | 2024 | 28 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 245 | 0.210 |
Why?
|
| Sequence Deletion | 1 | 2025 | 209 | 0.210 |
Why?
|
| Biopsy, Needle | 3 | 2011 | 225 | 0.200 |
Why?
|
| Gene-Environment Interaction | 1 | 2025 | 120 | 0.200 |
Why?
|
| Cytodiagnosis | 1 | 2003 | 47 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 142 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 7 | 1994 | 1028 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2024 | 314 | 0.200 |
Why?
|
| Health Policy | 1 | 2025 | 206 | 0.200 |
Why?
|
| Frozen Sections | 1 | 2003 | 50 | 0.200 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2003 | 2 | 0.200 |
Why?
|
| Paraffin Embedding | 6 | 2015 | 77 | 0.190 |
Why?
|
| Hepatitis B | 1 | 2023 | 77 | 0.190 |
Why?
|
| Embolism | 1 | 2023 | 32 | 0.190 |
Why?
|
| Lasers | 5 | 1991 | 101 | 0.190 |
Why?
|
| Young Adult | 10 | 2025 | 6930 | 0.190 |
Why?
|
| Hand Dermatoses | 2 | 2004 | 8 | 0.190 |
Why?
|
| Quality of Health Care | 2 | 2017 | 382 | 0.190 |
Why?
|
| Triamcinolone | 2 | 2007 | 20 | 0.190 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2022 | 5 | 0.180 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2023 | 72 | 0.180 |
Why?
|
| Darier Disease | 1 | 2022 | 5 | 0.180 |
Why?
|
| Hyperpigmentation | 1 | 2022 | 7 | 0.180 |
Why?
|
| Hair Diseases | 1 | 2022 | 9 | 0.180 |
Why?
|
| Reproducibility of Results | 7 | 2024 | 2715 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2007 | 353 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 1001 | 0.180 |
Why?
|
| Hospitals, Rural | 1 | 2021 | 8 | 0.180 |
Why?
|
| Leiomyoma | 1 | 2005 | 211 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2025 | 761 | 0.180 |
Why?
|
| Papillomaviridae | 2 | 2021 | 179 | 0.180 |
Why?
|
| Medical Assistance | 1 | 2021 | 2 | 0.180 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 1991 | 155 | 0.180 |
Why?
|
| Ki-67 Antigen | 6 | 2001 | 66 | 0.170 |
Why?
|
| Buprenorphine | 1 | 2022 | 52 | 0.170 |
Why?
|
| Immunoenzyme Techniques | 7 | 2006 | 293 | 0.170 |
Why?
|
| Nephrology | 1 | 2022 | 46 | 0.170 |
Why?
|
| Cooperative Behavior | 2 | 2024 | 192 | 0.170 |
Why?
|
| Hospitals, Urban | 1 | 2021 | 64 | 0.170 |
Why?
|
| Prognosis | 6 | 2021 | 3910 | 0.170 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2001 | 9 | 0.170 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1713 | 0.170 |
Why?
|
| DNA Damage | 3 | 2014 | 389 | 0.170 |
Why?
|
| DNA Repair | 3 | 2014 | 361 | 0.170 |
Why?
|
| Up-Regulation | 2 | 2021 | 730 | 0.170 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2021 | 49 | 0.170 |
Why?
|
| Cytosine | 1 | 2021 | 121 | 0.170 |
Why?
|
| Medicare | 2 | 2021 | 455 | 0.170 |
Why?
|
| Infant, Premature, Diseases | 1 | 2001 | 80 | 0.170 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 3828 | 0.160 |
Why?
|
| Focus Groups | 1 | 2021 | 184 | 0.160 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 29 | 0.160 |
Why?
|
| Pediatrics | 1 | 2024 | 385 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 543 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2020 | 31 | 0.160 |
Why?
|
| Hospices | 1 | 2019 | 8 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 1991 | 378 | 0.160 |
Why?
|
| Mucous Membrane | 1 | 2020 | 82 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 122 | 0.160 |
Why?
|
| Eccrine Glands | 2 | 2016 | 4 | 0.160 |
Why?
|
| Medicaid | 2 | 2024 | 258 | 0.150 |
Why?
|
| Medical Errors | 1 | 2020 | 94 | 0.150 |
Why?
|
| Bangladesh | 3 | 2025 | 339 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 103 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 203 | 0.150 |
Why?
|
| Neoplasms, Basal Cell | 1 | 1999 | 10 | 0.150 |
Why?
|
| Hydrocephalus | 1 | 2020 | 79 | 0.150 |
Why?
|
| Self-Management | 1 | 2020 | 44 | 0.150 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 1999 | 3 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2021 | 2440 | 0.150 |
Why?
|
| Thrombolytic Therapy | 1 | 2022 | 254 | 0.150 |
Why?
|
| Leg Dermatoses | 2 | 2009 | 7 | 0.150 |
Why?
|
| Radiation Dosage | 2 | 2020 | 229 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 441 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 111 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 328 | 0.150 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 305 | 0.150 |
Why?
|
| Doxycycline | 2 | 1990 | 37 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2014 | 366 | 0.150 |
Why?
|
| Laser Therapy | 3 | 2001 | 151 | 0.150 |
Why?
|
| Mitosis | 3 | 2016 | 150 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 57 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2001 | 313 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2015 | 361 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2024 | 9098 | 0.150 |
Why?
|
| beta Catenin | 1 | 2020 | 265 | 0.140 |
Why?
|
| Down-Regulation | 4 | 2021 | 524 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 624 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2025 | 646 | 0.140 |
Why?
|
| Stem Cell Factor | 1 | 1998 | 19 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1161 | 0.140 |
Why?
|
| Hypopigmentation | 1 | 1998 | 5 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 776 | 0.140 |
Why?
|
| Pharmacies | 1 | 2018 | 12 | 0.140 |
Why?
|
| Phenotype | 3 | 2020 | 2544 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 233 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2021 | 256 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 283 | 0.140 |
Why?
|
| Patient Safety | 1 | 2020 | 218 | 0.140 |
Why?
|
| Adenosine | 1 | 2021 | 275 | 0.140 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2802 | 0.140 |
Why?
|
| Cell Differentiation | 4 | 2013 | 1621 | 0.140 |
Why?
|
| Fingers | 1 | 1998 | 53 | 0.130 |
Why?
|
| Time Factors | 6 | 2021 | 5410 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2017 | 298 | 0.130 |
Why?
|
| Antioxidants | 2 | 2013 | 231 | 0.130 |
Why?
|
| Technology Transfer | 1 | 2017 | 5 | 0.130 |
Why?
|
| Melanins | 2 | 2015 | 22 | 0.130 |
Why?
|
| Mast Cells | 2 | 2014 | 96 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 66 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2014 | 96 | 0.130 |
Why?
|
| Mitochondria | 3 | 1990 | 612 | 0.130 |
Why?
|
| Behavior | 1 | 2017 | 85 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2018 | 579 | 0.130 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2017 | 12 | 0.130 |
Why?
|
| Scalp | 3 | 2021 | 70 | 0.130 |
Why?
|
| Antigens, CD | 3 | 1999 | 476 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2017 | 51 | 0.130 |
Why?
|
| Hypertension | 2 | 2021 | 757 | 0.130 |
Why?
|
| Sweat Gland Diseases | 1 | 2016 | 3 | 0.130 |
Why?
|
| Radiodermatitis | 1 | 2016 | 10 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2011 | 1917 | 0.120 |
Why?
|
| Ear, External | 1 | 1996 | 24 | 0.120 |
Why?
|
| Attitude | 1 | 2017 | 132 | 0.120 |
Why?
|
| Models, Psychological | 1 | 2017 | 164 | 0.120 |
Why?
|
| Trigeminal Nerve | 1 | 1996 | 14 | 0.120 |
Why?
|
| Neuritis | 1 | 1996 | 7 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 156 | 0.120 |
Why?
|
| Facial Dermatoses | 1 | 1996 | 15 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 7 | 2003 | 1395 | 0.120 |
Why?
|
| Nose Neoplasms | 1 | 1996 | 36 | 0.120 |
Why?
|
| Hospitals, Community | 1 | 2016 | 33 | 0.120 |
Why?
|
| Acyclovir | 1 | 1996 | 35 | 0.120 |
Why?
|
| Radiation Protection | 1 | 2016 | 27 | 0.120 |
Why?
|
| Child Abuse | 1 | 2017 | 93 | 0.120 |
Why?
|
| Leprosy, Borderline | 1 | 1996 | 1 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2018 | 494 | 0.120 |
Why?
|
| Homeostasis | 1 | 1998 | 460 | 0.120 |
Why?
|
| Chickenpox | 1 | 1995 | 12 | 0.120 |
Why?
|
| Nurses | 1 | 2016 | 42 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 579 | 0.120 |
Why?
|
| Self Report | 1 | 2017 | 328 | 0.120 |
Why?
|
| gp100 Melanoma Antigen | 4 | 2006 | 12 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 1995 | 40 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 1995 | 25 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2018 | 298 | 0.120 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 660 | 0.120 |
Why?
|
| Child, Preschool | 7 | 2017 | 3829 | 0.110 |
Why?
|
| Scleroderma, Localized | 1 | 2015 | 9 | 0.110 |
Why?
|
| Erythema | 5 | 2016 | 31 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 484 | 0.110 |
Why?
|
| Cornea | 1 | 2015 | 55 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1995 | 78 | 0.110 |
Why?
|
| Indoles | 1 | 2016 | 303 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 337 | 0.110 |
Why?
|
| Leiomyosarcoma | 2 | 2011 | 48 | 0.110 |
Why?
|
| Phagocytosis | 1 | 2015 | 111 | 0.110 |
Why?
|
| Autoantibodies | 2 | 2012 | 277 | 0.110 |
Why?
|
| Angiolipoma | 1 | 1994 | 1 | 0.110 |
Why?
|
| Infant, Newborn | 5 | 2023 | 2479 | 0.110 |
Why?
|
| Cell Nucleus | 5 | 2017 | 603 | 0.110 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 309 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2024 | 162 | 0.110 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2007 | 24 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1018 | 0.110 |
Why?
|
| Hemangioma, Capillary | 1 | 1994 | 8 | 0.110 |
Why?
|
| Porphyrins | 4 | 2000 | 37 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 381 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2014 | 454 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 24 | 0.110 |
Why?
|
| Mohs Surgery | 2 | 2005 | 27 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2016 | 331 | 0.110 |
Why?
|
| Hospital Administration | 1 | 2014 | 24 | 0.100 |
Why?
|
| Neoplasms | 2 | 2019 | 3169 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 137 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2014 | 47 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2015 | 285 | 0.100 |
Why?
|
| Monophenol Monooxygenase | 3 | 2006 | 9 | 0.100 |
Why?
|
| MART-1 Antigen | 3 | 2006 | 21 | 0.100 |
Why?
|
| Allergens | 1 | 2014 | 189 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 641 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 1996 | 364 | 0.100 |
Why?
|
| alpha-Tocopherol | 1 | 2013 | 9 | 0.100 |
Why?
|
| Selenomethionine | 1 | 2013 | 11 | 0.100 |
Why?
|
| Pathologists | 2 | 2024 | 40 | 0.100 |
Why?
|
| Blister | 1 | 2012 | 7 | 0.100 |
Why?
|
| Models, Biological | 3 | 2020 | 1768 | 0.100 |
Why?
|
| Desmoglein 3 | 1 | 2012 | 6 | 0.100 |
Why?
|
| Desmoglein 1 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 123 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 71 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2005 | 295 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 767 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2015 | 4560 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 438 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 229 | 0.090 |
Why?
|
| Antigens, Neoplasm | 4 | 2006 | 355 | 0.090 |
Why?
|
| Neurothekeoma | 1 | 2012 | 5 | 0.090 |
Why?
|
| Pandemics | 3 | 2024 | 873 | 0.090 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2012 | 13 | 0.090 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2012 | 14 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 220 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 1994 | 353 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 876 | 0.090 |
Why?
|
| Inflammation | 2 | 2017 | 1050 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2012 | 1931 | 0.090 |
Why?
|
| Metaplasia | 2 | 2016 | 39 | 0.090 |
Why?
|
| Scalp Dermatoses | 2 | 2001 | 10 | 0.090 |
Why?
|
| Macrophages | 1 | 2015 | 610 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 1234 | 0.090 |
Why?
|
| Melanoma-Specific Antigens | 2 | 2001 | 4 | 0.090 |
Why?
|
| Scapula | 2 | 2005 | 25 | 0.090 |
Why?
|
| Base Sequence | 5 | 2021 | 2220 | 0.090 |
Why?
|
| Niacinamide | 1 | 2011 | 101 | 0.090 |
Why?
|
| Keratosis, Seborrheic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Microscopy, Polarization | 1 | 2011 | 12 | 0.080 |
Why?
|
| Nevus, Intradermal | 4 | 2000 | 5 | 0.080 |
Why?
|
| Genes, p53 | 4 | 1995 | 108 | 0.080 |
Why?
|
| Tissue Engineering | 1 | 2013 | 202 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 97 | 0.080 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 44 | 0.080 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2011 | 17 | 0.080 |
Why?
|
| Consensus | 2 | 2023 | 368 | 0.080 |
Why?
|
| Mice | 10 | 2021 | 12269 | 0.080 |
Why?
|
| Fluorescent Dyes | 2 | 1990 | 257 | 0.080 |
Why?
|
| Data Collection | 1 | 2012 | 370 | 0.080 |
Why?
|
| Quality of Life | 2 | 2019 | 1780 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2585 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 887 | 0.080 |
Why?
|
| Animals | 16 | 2021 | 28155 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2001 | 68 | 0.080 |
Why?
|
| Microscopy, Electron | 3 | 2002 | 439 | 0.080 |
Why?
|
| Hair Removal | 2 | 2000 | 14 | 0.080 |
Why?
|
| Recurrence | 2 | 2011 | 1190 | 0.080 |
Why?
|
| Rhodamine 123 | 4 | 1990 | 8 | 0.080 |
Why?
|
| Pregnancy | 3 | 2025 | 3147 | 0.080 |
Why?
|
| Mycobacterium Infections | 1 | 1989 | 11 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 829 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 352 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1914 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 159 | 0.080 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1989 | 25 | 0.080 |
Why?
|
| Granuloma | 1 | 1989 | 64 | 0.080 |
Why?
|
| Hair Follicle | 2 | 2002 | 28 | 0.080 |
Why?
|
| Cell Line | 7 | 2014 | 2464 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2011 | 515 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2011 | 479 | 0.070 |
Why?
|
| Infant | 4 | 2023 | 3220 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2017 | 2121 | 0.070 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2008 | 10 | 0.070 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2009 | 11 | 0.070 |
Why?
|
| Photosensitivity Disorders | 1 | 1988 | 14 | 0.070 |
Why?
|
| Mitotic Index | 2 | 2016 | 22 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2025 | 1518 | 0.070 |
Why?
|
| Incidental Findings | 2 | 2007 | 97 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 1922 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 153 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2021 | 696 | 0.070 |
Why?
|
| Actins | 2 | 2005 | 467 | 0.070 |
Why?
|
| Vitiligo | 2 | 2006 | 19 | 0.070 |
Why?
|
| Transglutaminases | 2 | 2000 | 41 | 0.070 |
Why?
|
| Paired Box Transcription Factors | 1 | 2008 | 50 | 0.070 |
Why?
|
| Intermediate Filament Proteins | 2 | 2014 | 35 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2011 | 2017 | 0.070 |
Why?
|
| Leg | 2 | 2014 | 140 | 0.070 |
Why?
|
| Granular Cell Tumor | 1 | 2007 | 5 | 0.070 |
Why?
|
| Hyperkeratosis, Epidermolytic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2020 | 1117 | 0.070 |
Why?
|
| Epidermal Cyst | 1 | 2007 | 7 | 0.070 |
Why?
|
| Calcinosis | 1 | 2008 | 222 | 0.060 |
Why?
|
| Eosinophilic Granuloma | 1 | 2007 | 10 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 985 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2014 | 784 | 0.060 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2006 | 11 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2006 | 244 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 442 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 67 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2006 | 1061 | 0.060 |
Why?
|
| Sunburn | 2 | 2003 | 8 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2006 | 59 | 0.060 |
Why?
|
| Cell Survival | 5 | 2009 | 1004 | 0.060 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2005 | 21 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 626 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2020 | 960 | 0.060 |
Why?
|
| Precancerous Conditions | 2 | 2011 | 205 | 0.060 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2005 | 5 | 0.060 |
Why?
|
| Condylomata Acuminata | 1 | 2005 | 11 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 1995 | 572 | 0.060 |
Why?
|
| Tongue Neoplasms | 1 | 2005 | 51 | 0.060 |
Why?
|
| Nigeria | 1 | 2025 | 162 | 0.050 |
Why?
|
| Carcinoma in Situ | 2 | 2002 | 52 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2025 | 121 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 131 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2006 | 167 | 0.050 |
Why?
|
| Arm | 2 | 2003 | 97 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2000 | 666 | 0.050 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2016 | 40 | 0.050 |
Why?
|
| Democratic Republic of the Congo | 1 | 2023 | 8 | 0.050 |
Why?
|
| Hepatitis B Vaccines | 1 | 2023 | 17 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2023 | 26 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2006 | 470 | 0.050 |
Why?
|
| Policy | 1 | 2024 | 41 | 0.050 |
Why?
|
| Methadone | 1 | 2024 | 51 | 0.050 |
Why?
|
| Purpura | 1 | 2003 | 13 | 0.050 |
Why?
|
| Vaccines | 1 | 2024 | 84 | 0.050 |
Why?
|
| Cellulitis | 1 | 2003 | 18 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 154 | 0.050 |
Why?
|
| Vitamin E | 1 | 2003 | 34 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2003 | 40 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1995 | 156 | 0.050 |
Why?
|
| Cell Count | 2 | 2006 | 197 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2000 | 826 | 0.050 |
Why?
|
| Proteins | 2 | 1998 | 803 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 117 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2003 | 87 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 38 | 0.050 |
Why?
|
| Vaccination | 1 | 2024 | 304 | 0.050 |
Why?
|
| Carcinoma | 1 | 2005 | 439 | 0.050 |
Why?
|
| Dermatologic Agents | 1 | 2003 | 77 | 0.050 |
Why?
|
| Abdomen | 1 | 2003 | 120 | 0.050 |
Why?
|
| Eyebrows | 1 | 2022 | 10 | 0.050 |
Why?
|
| Retinoids | 1 | 2022 | 18 | 0.050 |
Why?
|
| Blood Vessels | 2 | 2008 | 91 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 19 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2022 | 48 | 0.040 |
Why?
|
| Penicillin G Benzathine | 1 | 2001 | 6 | 0.040 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2001 | 9 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 341 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2001 | 454 | 0.040 |
Why?
|
| Vulvar Diseases | 1 | 2001 | 8 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2022 | 118 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 25 | 0.040 |
Why?
|
| Patients | 1 | 2022 | 103 | 0.040 |
Why?
|
| Penicillins | 1 | 2001 | 24 | 0.040 |
Why?
|
| Polymers | 1 | 2023 | 218 | 0.040 |
Why?
|
| Sebaceous Gland Diseases | 1 | 2001 | 1 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2001 | 51 | 0.040 |
Why?
|
| Hair | 1 | 2001 | 55 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 19 | 0.040 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2021 | 14 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2001 | 51 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.040 |
Why?
|
| RNA Interference | 2 | 2014 | 379 | 0.040 |
Why?
|
| Sequestosome-1 Protein | 1 | 2021 | 23 | 0.040 |
Why?
|
| Genotype | 2 | 2017 | 1866 | 0.040 |
Why?
|
| Vacuoles | 1 | 2021 | 48 | 0.040 |
Why?
|
| Syphilis | 1 | 2001 | 35 | 0.040 |
Why?
|
| Necrosis | 1 | 2001 | 204 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 2000 | 14 | 0.040 |
Why?
|
| Protein Stability | 1 | 2021 | 103 | 0.040 |
Why?
|
| Psychometrics | 1 | 2022 | 337 | 0.040 |
Why?
|
| Trisomy | 1 | 2000 | 53 | 0.040 |
Why?
|
| Hirsutism | 1 | 2000 | 53 | 0.040 |
Why?
|
| Acanthosis Nigricans | 1 | 2000 | 3 | 0.040 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2000 | 23 | 0.040 |
Why?
|
| RNA Stability | 1 | 2021 | 97 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2000 | 83 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 54 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2022 | 237 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2001 | 159 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 128 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 3054 | 0.040 |
Why?
|
| Lysosomes | 1 | 2021 | 123 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2020 | 9 | 0.040 |
Why?
|
| Histological Techniques | 1 | 2000 | 33 | 0.040 |
Why?
|
| Ulcer | 1 | 2020 | 38 | 0.040 |
Why?
|
| Antigens, CD1d | 1 | 2020 | 32 | 0.040 |
Why?
|
| Collagen | 1 | 2002 | 304 | 0.040 |
Why?
|
| Steroids | 1 | 2021 | 168 | 0.040 |
Why?
|
| Light | 2 | 1999 | 288 | 0.040 |
Why?
|
| Fibroma | 1 | 2000 | 30 | 0.040 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2020 | 79 | 0.040 |
Why?
|
| Head | 1 | 2020 | 131 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 272 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 167 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 61 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 2012 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 254 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2000 | 129 | 0.040 |
Why?
|
| Tissue Fixation | 2 | 2015 | 39 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2020 | 132 | 0.040 |
Why?
|
| Cytokines | 2 | 2017 | 863 | 0.040 |
Why?
|
| Granuloma Annulare | 1 | 1999 | 3 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1999 | 287 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 68 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 150 | 0.040 |
Why?
|
| Overweight | 1 | 2020 | 120 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 1173 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 413 | 0.040 |
Why?
|
| Amyloid | 1 | 1999 | 104 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2019 | 41 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1999 | 104 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2001 | 497 | 0.040 |
Why?
|
| Learning | 1 | 2001 | 293 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 457 | 0.040 |
Why?
|
| Caregivers | 1 | 2020 | 180 | 0.040 |
Why?
|
| Mucinosis, Follicular | 1 | 1998 | 2 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 896 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 1999 | 118 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2021 | 408 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1998 | 16 | 0.030 |
Why?
|
| Elbow | 1 | 1998 | 12 | 0.030 |
Why?
|
| Communication | 1 | 2021 | 434 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 920 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 889 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 688 | 0.030 |
Why?
|
| Syndrome | 2 | 1996 | 437 | 0.030 |
Why?
|
| Biomarkers | 3 | 2015 | 1910 | 0.030 |
Why?
|
| Neutrophils | 2 | 1996 | 324 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 77 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2000 | 506 | 0.030 |
Why?
|
| Disease Progression | 2 | 2006 | 1531 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 3110 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2017 | 22 | 0.030 |
Why?
|
| Attention | 1 | 2001 | 411 | 0.030 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1997 | 41 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1998 | 164 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 1998 | 371 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1998 | 191 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 502 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 482 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2017 | 71 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2018 | 660 | 0.030 |
Why?
|
| Dermatitis, Contact | 1 | 1996 | 9 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 174 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 64 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 31 | 0.030 |
Why?
|
| Lymphangiogenesis | 1 | 2017 | 41 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 61 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 99 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1524 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 88 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 353 | 0.030 |
Why?
|
| British Columbia | 1 | 2016 | 10 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1105 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 375 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 1996 | 21 | 0.030 |
Why?
|
| Vimentin | 1 | 1996 | 47 | 0.030 |
Why?
|
| Cranial Nerve Diseases | 1 | 1996 | 9 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 1996 | 33 | 0.030 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 22 | 0.030 |
Why?
|
| Cystitis, Interstitial | 1 | 1997 | 55 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 38 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2020 | 548 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1243 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2017 | 131 | 0.030 |
Why?
|
| Dominican Republic | 1 | 1996 | 3 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 140 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 86 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1995 | 10 | 0.030 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1995 | 11 | 0.030 |
Why?
|
| New York City | 1 | 1996 | 69 | 0.030 |
Why?
|
| Herpesvirus 2, Human | 1 | 1995 | 20 | 0.030 |
Why?
|
| Emigration and Immigration | 1 | 1996 | 49 | 0.030 |
Why?
|
| Desmin | 1 | 1995 | 10 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 154 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 1995 | 21 | 0.030 |
Why?
|
| Sebaceous Glands | 1 | 1995 | 28 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1996 | 278 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1995 | 29 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1996 | 308 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 1995 | 68 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 314 | 0.030 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1995 | 18 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1170 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1996 | 183 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2026 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1723 | 0.030 |
Why?
|
| Genome, Human | 1 | 2020 | 823 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 1997 | 344 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 350 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 289 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2020 | 3502 | 0.030 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2014 | 26 | 0.030 |
Why?
|
| Epithelium | 1 | 1995 | 316 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 3435 | 0.030 |
Why?
|
| Granuloma, Pyogenic | 1 | 1994 | 4 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 504 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2017 | 331 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2000 | 1261 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1995 | 416 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2014 | 148 | 0.030 |
Why?
|
| Lipoma | 1 | 1994 | 25 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1996 | 234 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2001 | 1073 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 131 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 118 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 962 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 361 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 1995 | 212 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 352 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 917 | 0.020 |
Why?
|
| Immunophenotyping | 2 | 2006 | 224 | 0.020 |
Why?
|
| Patient Preference | 1 | 2014 | 125 | 0.020 |
Why?
|
| Point Mutation | 1 | 1994 | 238 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 1534 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 436 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 2755 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2010 | 2850 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1999 | 1415 | 0.020 |
Why?
|
| Thorax | 1 | 2012 | 78 | 0.020 |
Why?
|
| Oncogenes | 1 | 1992 | 100 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 546 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1995 | 663 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2495 | 0.020 |
Why?
|
| Gene Expression | 3 | 2008 | 1301 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Chlorophyllides | 3 | 2000 | 5 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 1992 | 948 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2011 | 35 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 122 | 0.020 |
Why?
|
| Kinetics | 2 | 1991 | 1492 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2010 | 756 | 0.020 |
Why?
|
| Mitochondrial Swelling | 1 | 1990 | 4 | 0.020 |
Why?
|
| Photolysis | 1 | 1990 | 13 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 217 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 1998 | 1275 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1990 | 13 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2011 | 210 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1990 | 125 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1990 | 39 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1992 | 424 | 0.020 |
Why?
|
| Pigmentation | 2 | 2006 | 76 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 1992 | 375 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1989 | 41 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2006 | 481 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 555 | 0.020 |
Why?
|
| Caspases | 1 | 2009 | 151 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1990 | 281 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1729 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2009 | 45 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1988 | 28 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 200 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 84 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 674 | 0.020 |
Why?
|
| PAX3 Transcription Factor | 1 | 2008 | 11 | 0.020 |
Why?
|
| Genome | 1 | 2010 | 407 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 290 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2008 | 170 | 0.020 |
Why?
|
| Acanthoma | 1 | 2007 | 1 | 0.020 |
Why?
|
| Formaldehyde | 2 | 1999 | 51 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 1988 | 436 | 0.020 |
Why?
|
| Microspheres | 3 | 1991 | 88 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1999 | 3476 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 124 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1985 | 0.020 |
Why?
|
| Procollagen | 1 | 2005 | 8 | 0.010 |
Why?
|
| Low-Level Light Therapy | 1 | 2005 | 15 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2006 | 319 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 208 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 429 | 0.010 |
Why?
|
| Paget Disease, Extramammary | 1 | 2004 | 8 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 178 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 234 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2365 | 0.010 |
Why?
|
| Risk Factors | 2 | 2006 | 5898 | 0.010 |
Why?
|
| Pyrimidine Dimers | 1 | 2003 | 4 | 0.010 |
Why?
|
| Pedigree | 2 | 1999 | 961 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 200 | 0.010 |
Why?
|
| Infliximab | 1 | 2003 | 162 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 2910 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2002 | 43 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 656 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2006 | 2544 | 0.010 |
Why?
|
| Cell Division | 2 | 1995 | 693 | 0.010 |
Why?
|
| Vulva | 1 | 2001 | 23 | 0.010 |
Why?
|
| Treponema pallidum | 1 | 2001 | 8 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 588 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1982 | 159 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2001 | 92 | 0.010 |
Why?
|
| Venules | 1 | 2001 | 6 | 0.010 |
Why?
|
| Dermis | 1 | 2001 | 30 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2001 | 103 | 0.010 |
Why?
|
| Axilla | 1 | 2001 | 109 | 0.010 |
Why?
|
| Edema | 1 | 2001 | 70 | 0.010 |
Why?
|
| Veins | 1 | 2001 | 87 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 292 | 0.010 |
Why?
|
| Karyotyping | 1 | 2000 | 222 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2000 | 49 | 0.010 |
Why?
|
| Nuclear Proteins | 2 | 1995 | 740 | 0.010 |
Why?
|
| Peripherins | 1 | 2000 | 4 | 0.010 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2000 | 3 | 0.010 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2000 | 3 | 0.010 |
Why?
|
| Liposarcoma | 1 | 2000 | 10 | 0.010 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2000 | 11 | 0.010 |
Why?
|
| Sclerosis | 1 | 2000 | 31 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 399 | 0.010 |
Why?
|
| Movement | 1 | 2001 | 304 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 1999 | 3 | 0.010 |
Why?
|
| Viral Matrix Proteins | 1 | 1999 | 13 | 0.010 |
Why?
|
| COS Cells | 1 | 1999 | 164 | 0.010 |
Why?
|
| Histiocytes | 1 | 1999 | 22 | 0.010 |
Why?
|
| Connective Tissue | 1 | 1999 | 22 | 0.010 |
Why?
|
| Giant Cells | 1 | 1999 | 18 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1999 | 82 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1999 | 80 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1999 | 65 | 0.010 |
Why?
|
| Patella | 1 | 1999 | 30 | 0.010 |
Why?
|
| Virus Activation | 1 | 1999 | 36 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 712 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1999 | 212 | 0.010 |
Why?
|
| Tibia | 1 | 1999 | 80 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1999 | 352 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2000 | 824 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1999 | 331 | 0.010 |
Why?
|
| Ligands | 1 | 1999 | 476 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 111 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 880 | 0.010 |
Why?
|
| Cytarabine | 1 | 1998 | 216 | 0.010 |
Why?
|
| Gastrectomy | 1 | 1997 | 71 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 1997 | 34 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1997 | 80 | 0.010 |
Why?
|
| Esophagoscopy | 1 | 1997 | 91 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1998 | 284 | 0.010 |
Why?
|
| Esophagus | 1 | 1997 | 113 | 0.010 |
Why?
|
| Trioxsalen | 1 | 1976 | 2 | 0.010 |
Why?
|
| Endosonography | 1 | 1997 | 100 | 0.010 |
Why?
|
| Methoxsalen | 1 | 1976 | 15 | 0.010 |
Why?
|
| Coumarins | 1 | 1976 | 14 | 0.010 |
Why?
|
| Esophagectomy | 1 | 1997 | 92 | 0.010 |
Why?
|
| Ultraviolet Therapy | 1 | 1976 | 17 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1999 | 1133 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1998 | 244 | 0.010 |
Why?
|
| Crohn Disease | 1 | 2003 | 808 | 0.010 |
Why?
|
| Acantholysis | 1 | 1996 | 1 | 0.010 |
Why?
|
| Remission Induction | 1 | 1998 | 738 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 1701 | 0.010 |
Why?
|
| Leukemia | 1 | 1998 | 301 | 0.010 |
Why?
|
| Fixatives | 1 | 1995 | 12 | 0.010 |
Why?
|
| Radiography | 1 | 1997 | 790 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1995 | 106 | 0.010 |
Why?
|
| Porokeratosis | 1 | 1994 | 3 | 0.010 |
Why?
|
| Keratoacanthoma | 1 | 1994 | 4 | 0.010 |
Why?
|
| Contrast Media | 1 | 1999 | 988 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1994 | 86 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1994 | 95 | 0.010 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 1992 | 6 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1992 | 42 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 1994 | 342 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1992 | 96 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1992 | 135 | 0.010 |
Why?
|
| Clone Cells | 1 | 1992 | 219 | 0.010 |
Why?
|
| Exons | 1 | 1994 | 450 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1992 | 134 | 0.010 |
Why?
|
| Latex | 1 | 1991 | 2 | 0.010 |
Why?
|
| Methionine Sulfoximine | 1 | 1991 | 1 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 894 | 0.010 |
Why?
|
| Buthionine Sulfoximine | 1 | 1991 | 7 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1992 | 149 | 0.010 |
Why?
|
| Spleen | 1 | 1992 | 374 | 0.010 |
Why?
|
| Hair Color | 1 | 1990 | 8 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1994 | 826 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2001 | 2562 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1989 | 163 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1990 | 1014 | 0.000 |
Why?
|
| Transcription Factors | 1 | 1994 | 1691 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1976 | 657 | 0.000 |
Why?
|